Cognitive Correlates of Antidepressant Treatment Response in Elders

Depression Clinical Trial

Official title:

Determining the Impact of Dementia and Executive Impairment on Antidepressant Treatment Response in Older Persons

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01477268
• Other study ID #: 06-296
• Status: Completed
• Phase: Phase 4
• First received: June 9, 2009
• Last updated: November 18, 2011
• Start date: June 2007
• Est. completion date: October 2009

Study information

• Verified date: May 2011
• Source: St. Michael's Hospital, Toronto
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Ethics Review Committee
• Study type: Interventional

Clinical Trial Summary

Major depression is a very common health problem affecting older persons. The present standard of treatment is with medications called "antidepressants". Antidepressants have been studied extensively in older persons with normal brain function and have been shown to be effective. However, certain types of brain dysfunction called "executive impairment" (inability to do higher order thinking) may lead to poor treatment outcomes. This study will compare how older depressed people with different levels of executive impairment respond differently to standard antidepressant treatment. Knowing this information will lead to more rational targeting of available treatments, leading to improved treatment outcomes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: October 2009
• Est. primary completion date: April 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 65 Years to 90 Years

Eligibility

Inclusion Criteria:

• above the age of 65,

• speak English fluently,

• experience depression, AND

• not yet on active treatment.

Exclusion Criteria:

• active delirium,

• substance abuse,

• mental illness other than major depression,

• active CNS disease,

• unstable systematic medical disease, OR

• current of past psychotic disorder.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Depression

Intervention

Drug:
• Zoloft (antidepressant)
Zoloft 50-200 mg po od x 12 weeks

Locations

Country	Name	City	State
Canada	St Michael's Hospital	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
St. Michael's Hospital, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	depression		June 1, 2007 - June 1, 2008	No